Ventyx Biosciences is a biopharmaceutical company focusing on developing small molecule product candidates for autoimmune disorders and inflammatory diseases. The company's lead product candidate, VTX958, is in phase I clinical trials targeting immune-mediated diseases such as lupus and psoriasis. Ventyx Biosciences also develops other potential treatments for ulcerative colitis and systemic inflammatory diseases, and CNS-penetrant inhibitors for multiple sclerosis, Parkinson disease, amyotrophic lateral sclerosis, and Alzheimer disease.